HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Institute for Genetic Medicine >
Peer-reviewed Journal Articles, etc >

Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.

Files in This Item:
II19-2-151.pdf444.92 kBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
Authors: Zhang, Yue Browse this author
Wakita, Daiko Browse this author
Chamoto, Kenji Browse this author
Narita, Yoshinori Browse this author
Matsubara, Naoki Browse this author
Kitamura, Hidemitsu Browse this author
Nishimura, Takashi Browse this author →KAKEN DB
Keywords: Th1 cell
tumor-specific CTL
tumor vaccination therapy
Issue Date: Feb-2007
Publisher: Oxford University Press
Journal Title: International Immunology
Volume: 19
Issue: 2
Start Page: 151
End Page: 161
Publisher DOI: 10.1093/intimm/dxl132
PMID: 17189593
Abstract: We have previously described a method for adoptive immunotherapy of cancer based on antigen-specific Th1 cells. However, efficient induction of anti-tumor responses using Th1 cells remains a formidable challenge, especially for MHC class II-negative tumors. In the present study, we sought to develop a novel strategy to eradicate established tumors of the MHC class II-negative, ovalbumin (OVA)-expressing EG-7 cells. Tumor-bearing mice were intradermally treated with OVA-specific Th1 cells, combined with the model tumor antigen (OVA), near the tumor-draining lymph node (DLN). We found that tumor growth was significantly inhibited by this strategy and 50–60% of tumor-bearing mice were completely cured. Tumor eradication was crucially dependent on the generation of OVA/H-2Kb-specific CTLs in the tumor DLNs and tumor site. The injected Th1 cells were mainly distributed in tumor DLNs, where they vigorously proliferated and enhanced the activation of dendritic cells. Strikingly, we also found that the accumulation of CD4+CD25+ regulatory T cells (Tregs) was significantly inhibited in tumor DLNs by Th1 cell adjuvant therapy and this abrogation was associated with IFN secreted by Th1 cells. These results identify Th1 cell adjuvant therapy combined with tumor vaccination as a novel approach to the treatment of human cancer.
Rights: This is a pre-copy-editing, author-produced PDF of an article accepted for publication in International Immunology following peer review. The definitive publisher-authenticated version Oxford University Press, International Immunology, 19, 2, 2007, 151-161 is available online at:
Type: article (author version)
Appears in Collections:遺伝子病制御研究所 (Institute for Genetic Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 西村 孝司

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University